Abstract
Backgroud: To investigate the relevance of anti-SSA and/or anti-SSB antibodies to pregnancy in Chinese patients.
Methods: This retrospective study proceeded at Ren Ji Hospital, Shanghai, China, from January 2018 to December 2020. 476 patients with anti-SSA and/or anti-SSB antibodies and 100 healthy donors were enrolled. The studying groups are divided into 5 subgroups: Ro 52 group, Ro 60 group, Ro 52 + Ro 60 group, SSB group, and SSA+ SSB group. The distribution characteristics of anti-SSA and anti-SSB antibodies as well as the relevance of anti-SSA and anti-SSB antibodies to adverse pregnancy history were recorded.
Results: There was no significant difference in age and BMI between the study groups and the control group, p＞0.05. Among 476 patients, 469 (98.5%) were anti-SSA antibody-positive including Ro 52 positive 20.4% (97/476), Ro 60 positive 34.9% (166/476), Ro 52+Ro 60 29.8% (142/476). 7 were anti-SSB antibody positive (1.5%). Both anti-SSA and anti-SSB positive was 13.4% (64/476). The most common adverse pregnancy history in the study groups was intrauterine death (>20 gw). Previous CHB all occurred in SSA + SSB group. SS is the most common diagnosis of anti-SSA and/or anti-SSB antibodies-positive patients; The rate of therapeutic abortion and preterm birth was higher than in the control group, while the gestational week of delivery and neonatal weight was significantly lower than the control group, p＜0.05.
Conclusion: Anti-SSA and/or anti-SSB antibodies increase the risks of obstetric complications and poor outcomes of pregnancy.